Synergistic interaction between oxaliplatin (L-OHP) and 5-Fluorouracil (5-FU)

被引：0
|
作者：
Ward, S [1 ]
Papamichael, D [1 ]
Locke, K [1 ]
Darke, C [1 ]
Joel, S [1 ]
机构：
[1] St Bartholomews Hosp, Dept Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
187
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic (PK) interaction between 5-fluorouracil (5-FU) and oxaliplatin (L-OHP).
    Papamichael, D
    Joel, SP
    Seymour, M
    Richards, F
    Bowerbank, M
    Slevin, ML
    BRITISH JOURNAL OF CANCER, 1998, 78 : 12 - 12
  • [2] Oxaliplatin (L-OHP) does not influence the pharmacokinetics of 5-fluorouracil (5-FU)
    Joel, SP
    Richards, F
    Halstead, F
    Seymour, M
    BRITISH JOURNAL OF CANCER, 2000, 83 : 68 - 68
  • [3] Oxaliplatin (L-OHP) in combination with leucovorin (LV) and 5-fluorouracil (5FU) in pretreated metastatic colorectal cancer (CRC) patients (PTS).
    Di Stefano, A
    Calandri, C
    Benedetti, G
    Poggi, B
    Mazzoni, F
    Marrocolo, F
    Spagnuolo, P
    Rimondini, S
    Crinò, L
    ANNALS OF ONCOLOGY, 2000, 11 : 68 - 68
  • [4] Weekly administration of 5-fluorouracil (5-FU), folinic acid (FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) [FUFOXIRI] for patients with metastatic gastric or colorectal cancer
    Harba, A
    Peinert, S
    Grothe, W
    Jordan, K
    Kegel, T
    Mueller, LP
    Behrens, R
    Grothey, A
    Arnold, D
    Schmoll, HJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 300S - 300S
  • [5] Addition of oxaliplatin (L-OHP(R)) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC)
    Garufi, C
    Bensmaine, MA
    Brienza, S
    Misset, JL
    Aschelter, A
    Pace, R
    BertheaultCvitkovic, F
    Terzoli, E
    Levi, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 124 - 124
  • [6] Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.
    Souglakos, J
    Kouroussis, C
    Ziras, N
    Malamos, N
    Potamianou, A
    Mavroudis, D
    Kakolyris, S
    Androulakis, N
    Vardakis, N
    Georgoulias, V
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [7] Oxaliplatin (L-OHP) combined with continous infusion 5-fluorouracil (5-FU) and folinic acid (FA) based regimen in advanced colorectal cancer patients, confirmatory data on efficacy and toxicity
    Bochicchio, AM
    Capobianco, AML
    Coccaro, M
    Colasuonno, L
    Di Leo, P
    Galasso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 64 - 64
  • [8] Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil (5-FU) or 5-FU/oxaliplatin (5FU/OX) for rectal cancer
    Dolinsky, CM
    Mahmoud, NN
    Mick, R
    Sun, W
    Whittington, RW
    Solin, LJ
    Haller, DG
    Fry, RD
    Metz, JM
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (02): : S277 - S277
  • [9] SYNERGISTIC LETHAL EFFECTS OF ENDOTOXIN AND 5-FLUOROURACIL (5-FU) IN MOUSE
    NOVAK, D
    DRUMMOND, D
    MUNSON, AE
    JOURNAL OF THE RETICULOENDOTHELIAL SOCIETY, 1973, 13 (04): : 354 - 354
  • [10] Bi-fractionated oxaliplatin (L-OHP) plus 5-fluorouracil (5FU)/leucovorin (LV) for elderly patients (pts) with advanced colorectal cancer (CRC).
    Massacesi, C
    Lippe, P
    Recchia, F
    Marcucci, F
    Rocchi, M
    Cesta, A
    Pilone, A
    Cappelletti, C
    Bonsignori, M
    Mattioli, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
12345